Clinical trial requests to Infarmed rise to 115 in the first half of the year

Infarmed received 115 requests to conduct clinical trials in the first half of 2025, a slight increase compared to the same period in 2024.

Of the more than 100 requests, Infarmed has already authorized 93, according to data from that entity, cited by the Lusa news agency.

The increase in the number of requests “reinforces Portugal’s position as an attractive country for carrying out clinical research in a European context”.

The therapeutic area associated with the majority of requests is related to oncology, with 38 trials requested, followed by studies related to diseases of the immune system (14) and the nervous system (9).

For Infarmed, therapeutic diversity "demonstrates the growing interest on the part of promoters in developing clinical research in multiple areas of health, contributing to scientific advancement and patient access to new therapies."

The authority also emphasizes that more than ninety requests have already been authorized, which reflects the commitment “to promote a simultaneously rigorous and rapid evaluation, in close coordination with the Ethics Committee for Clinical Research (CEIC)”.

In single-national trials, the average authorization time was 31 days, according to Infarmed.